Arima Genomics logo — Gain unparalleled access to the sequence + structure of any...

Arima Genomics

Gain unparalleled access to the sequence + structure of any genome

Founded 2015 United States Carlsbad, United States 45 employees Series C Total: $29.00M Biotechnology, Health Care +1

General Information

Company Name Arima Genomics
Founded Year 2015
Location United States Carlsbad, United States
Employees 45
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Series C
Business Model B2B, B2B2C, Platform
Revenue Model Service Fee, Product Sales, Project Based
Social

BounceWatch is an independent company data service, not affiliated with Arima Genomics. To contact Arima Genomics, visit arimagenomics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Arima Genomics compare?

A PDF of Arima Genomics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Arima Genomics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Arima Genomics

Arima Genomics, founded in 2015, is a promising player in the Biotechnology, Health Care, and Life Sciences sectors. Headquartered in the United States, the company is pioneering advancements in 3D genomics with its offering, which allows users to "Gain unparalleled access to the sequence + structure of any genome."

Specializing in analyzing the spatial and temporal changes in the 3D structure of genomes, Arima Genomics seeks to unlock new dimensions of gene regulation and cellular function, positioning itself as a transformative force in genomics research and applications.

The company secured a significant funding round with a $7.00M Series B investment on 15 March 2022. Notable investors include Tech Coast Angels, Cowin Venture, Berkeley Catalyst Fund, Genetron Health, Ladder Ventures, Hiaqua Investments, Vectr, and Agilent Technologies. This capital injection signals strong confidence in Arima’s growth potential and industry impact.

Business keywords: 3D Genomics, Molecular Biology, Genomics, Sequencing, Genome sequencing, HiC-Sequencing, Genome structure, Gene regulation, Human health, Hi-C technology, Chromosome-scale assemblies, Spatial genome changes, Temporal genome changes, Bioinformatics analysis

Services & Products

Aventa Clinical Testing
Structural Insight into Cancer Genomes
Therapeutic Development Consultation
Biopharma Collaborative Research

Target Customers

Oncologists Biopharma Companies Clinical Researchers Cancer Treatment Centers

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $22.00M 5
Illumina Ventures, Cowin Venture +3
01 Jun 2025
Series B $7.00M 8
Tech Coast Angels, Vectr Ventures +6
01 Mar 2022
Series A Undisclosed 4
Vectr Ventures, Cowin Venture +2
01 Feb 2020
Spinout Undisclosed 1
University Ventures
01 Jan 2015

Arima Genomics Alternatives & Competitors

View All Alternatives
Arima Genomics vs

The Pioneers in Molecular Cartography

Series B
69 employees
Biotechnology, Health Care
Arima Genomics vs

Genlerinize Işık Tutuyoruz!

71 employees
Biotechnology, Life Sciences
Arima Genomics vs
Ultima Genomics
Ultima Genomics United States

Unleashing the power of genomics at scale

Seed
305 employees
Biotechnology, Health Care

FAQ About Arima Genomics

Gain unparalleled access to the sequence + structure of any genome
Arima Genomics was founded in 2015.
Arima Genomics is headquartered in Carlsbad, United States.
Arima Genomics operates in Biotechnology, Health Care and Life Sciences. Its work centres on 3D Genomics, Molecular Biology, Genomics and Sequencing. Its customers include Oncologists, Biopharma Companies and Clinical Researchers.
Arima Genomics has a B2B, B2B2C and Platform business model. Its revenue comes from Service Fee, Product Sales and Project Based.
Arima Genomics has approximately 45 employees.
Arima Genomics has completed 4 funding rounds, raising a total of $29.00M. The latest funding stage is Series C.
Arima Genomics offers: Aventa Clinical Testing, Structural Insight into Cancer Genomes, Therapeutic Development Consultation, Biopharma Collaborative Research.
Top alternatives and competitors to Arima Genomics include Resolve Biosciences, Genoks Genetik Hastalıklar Değerlendirme Merkezi, Ultima Genomics, Single Technologies, Earlham Institute. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Arima Genomics and Resolve Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Arima Genomics, https://bouncewatch.com/company/arima-genomics, updated 22 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes